Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03811366) enrolled 12 participants, all of whom completed the study — none dropped out. All participants received corticosteroid monotherapy (treatment with steroids only, without other medicines). The trial was measuring the health of the retina (the light-sensitive layer at the back of the eye) using a test called an electroretinogram (ERG), which records the electrical signals the retina produces in response to light. These measurements were taken at 12 months and again at 24 months. The trial also tracked other signs of eye inflammation, including cells in the front of the eye, changes seen on specialised eye scans, and changes in the thickness of a layer at the back of the eye called the choroid. The reported data shows that, at 12 months, the median (middle value) ERG readings for the group ranged from 42 to 508 microvolts across the different signal types measured. At 24 months, those readings ranged from 43 to 484 microvolts. When comparing the 24-month readings to the 12-month readings, the trial divided participants into two subgroups: those whose ERG readings stayed relatively stable, and those whose readings worsened (defined as a drop of 30% or more in any measured signal). The reported data shows the stable group had changes ranging from 0% to +9.5% (little to no change), while the worsening group had changes ranging from approximately −5% to −47.1% (a decline in those readings). For the secondary measurements, the reported data shows that in the stable ERG group, 8 eyes had a recurrence or worsening of inflammatory cells at the front of the eye, compared with 0 eyes in the worsening ERG group. For the specialised eye scan (indocyanine green angiography), 17 eyes in the stable group and 5 eyes in the worsening group showed an increase in a score used to measure inflammation-related changes. For choroidal thickness, 8 eyes in the stable group and 4 eyes in the worsening group showed an increase of 30% or more. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 26875727) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed by a doctor with Vogt-Koyanagi-Harada disease (a condition that affects the eyes and other parts of the body)
- Your condition started recently and you have not received any treatment for it yet
Who may not be able to join:
- Your Vogt-Koyanagi-Harada disease did not start recently (i.e., it is in a later or chronic stage)
- You have cloudiness or haziness in the parts of the eye that light passes through, such as the lens or the fluid inside the eye (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Median Values of ERG Scotopic Parameters at 12-month; Median Values of ERG Scotopic Parameters at 24-month; Variation (Worsening or Improvement) Between 24 and 12 Months of ERG Scotopic Parameters Comparing 24 and 12-months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.